Pharmacovigilance Market Analysis: Key Service Providers & Growth Drivers

According to IMARC Group's latest research publication, The global pharmacovigilance market size was valued at USD 8.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 16.3 Billion by 2034, exhibiting a CAGR of 7.5% from 2026-2034.

How AI is Reshaping the Future of Pharmacovigilance Market

• Automated Adverse Event Detection and Case Intake: NLP-powered systems scan emails, clinical notes, and social media to automatically extract and flag adverse drug reactions.
• Signal Detection and Risk Prediction: Machine learning algorithms continuously scan databases like FAERS and VigiBase to spot unusual patterns in drug reactions.
• Regulatory Reporting and Compliance Automation: AI-driven platforms auto-generate safety reports that meet FDA, EMA, and other agency standards.

Stay Ahead with Updated 2026 Market Intelligence

Pharmacovigilance Industry Overview:

The global pharmacovigilance landscape is being reshaped by tightening regulatory frameworks and a sharp rise in drug complexity. The FDA launched its Emerging Drug Safety Technology Program to explore how AI can strengthen post-market surveillance, while the EMA published guidelines in 2024 specifically addressing AI adoption in safety monitoring. India added its own layer with the launch of ADRMS software under the Digital India initiative the country's first centralized adverse event database.

Pharmacovigilance Market Trends & Drivers

The surge in adverse drug reactions and polypharmacy is quietly becoming one of the biggest forces behind pharmacovigilance demand. With 129 million Americans living with at least one chronic condition, patients are routinely prescribed multiple medications and every new combination brings fresh safety risks.

Regulatory agencies worldwide are raising the bar on drug safety, and companies are feeling the pressure. The FDA's Sentinel Initiative is deploying AI-powered tools to detect adverse events faster than ever, while the EMA's Pharmacovigilance Risk Assessment Committee continues to tighten reporting standards across EU member states. India's CDSCO and Brazil's ANVISA are following suit with their own updated compliance mandates.

Outsourcing is no longer a cost-cutting move, it's become a strategic necessity. Contract outsourcing holds a commanding 61.2% share of the pharmacovigilance services market, and the reasons are straightforward. Building and maintaining a world-class in-house safety team is expensive, and the regulatory landscape shifts fast.

Leading Companies Operating in the Global Pharmacovigilance Industry:

• Accenture plc
• ArisGlobal LLC
• BioClinica Inc. (Cinven Partners LLP)
• Capgemini
• Cognizant
• International Business Machines Corporation
• ICON plc.
• IQVIA Inc.
• ITClinical
• Parexel International Corporation
• Wipro Limited

Pharmacovigilance Market Report Segmentation:

By Service Provider:

• In-house
• Contract Outsourcing

Contract outsourcing is the leading segment, holding a 61.2% market share, driven by its cost efficiency and access to specialized regulatory expertise.

By Product Life Cycle:

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Phase IV (post-marketing surveillance) dominates with a 76.5% market share, as ongoing safety monitoring of approved drugs remains a regulatory requirement.

By Type:

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Spontaneous reporting leads the segment with a 31.9% share, owing to its widespread adoption and role in rapid adverse event identification.

By Process Flow:

• Case Data Management
• Signal Detection
• Risk Management System

Signal detection is the largest segment at 38.2% market share, as it plays a central role in identifying and managing drug safety concerns.

By Therapeutic Area:

• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

Oncology leads with a 27.8% market share, driven by the high volume of cancer drug trials and the complexity of therapies like immunotherapies.

By End Use:

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Companies
• Others

Pharmaceutical companies hold the largest share at 44.2%, given their core responsibility for drug safety, regulatory compliance, and risk management across product lifecycles.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America leads the market with a 33.7% share, supported by advanced healthcare infrastructure and the FDA's stringent drug safety frameworks.

Recent News and Developments in Pharmacovigilance Market

• March 2025: Tech Mahindra and NVIDIA joined forces to launch an agentic AI-powered pharmacovigilance solution built on Tech Mahindra's TENO framework. The platform automates case intake, data transformation, and compliance workflows — cutting turnaround times by 40%, boosting data accuracy by 30%, and reducing operational costs by 25%.
• March 2025: ArisGlobal rolled out three new AI-driven products at its Breakthrough 2025 event: LifeSphere Unify, NavaX Insights, and Advanced Compliance Docs. These tools are designed to push the boundaries of what's possible in automated regulatory operations and pharmacovigilance.
• March 2025: LSK Global Pharma Services, a leading Korean CRO, selected Oracle Argus to overhaul its pharmacovigilance and safety case management systems. The partnership is aimed at speeding up drug safety analysis and meeting the evolving demands of global regulators.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.